PubMed Health⌕ Search

Biomedical subjects

S Simmons-Alling

Publications and source records attributed to S Simmons-Alling.

24 records · Page 2Linked to original sources

Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man.

The neurochemical specificity of physiological, biochemical, and psychological responses to dextroamphetamine was tested by pretreating volunteers with haloperidol (0.014 mg/kg IM), propranolol (0.1 mg/kg IV), thymoxamine (0.1 mg/kg IV), or placebo prior to 0.3 mg/kg IV amphetamine. Healthy volunteers (N = 12) participated in the studies, but not all volunteers received each drug combination. Haloperidol prevented dextroamphetamine-induced behavioral excitation, but did not significantly affect plasma norepinephrine or pressor responses, whereas propranolol inhibited norepinephrine and pressor responses without influencing excitation or other behavioral responses. Thymoxamine did not affect any of the responses measured. None of the agents significantly affected plasma cortisol or growth hormone responses. The prolactin rise following dextroamphetamine was potentiated by haloperidol. The results are consistent with the hypothesis that behavioral excitation after dextroamphetamine occurs through a dopaminergic mechanism, and pressor responses through a noradrenergic mechanism.

Adult↗

Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients.

Cholinergic supersensitivity has been postulated to be an etiologic factor in affective disorder. After several pilot dose-response studies, we administered 8 mg of the cholinergic agonist arecoline subcutaneously to eight pairs of normal volunteer identical twins and eight bipolar patients currently euthymic and unmedicated. During the hour following arecoline administration, the Profile of Mood States (POMS) showed an increase in total mood disturbance in both patient and control groups. Mean systolic blood pressure, pulse, plasma cortisol, prolactin, and growth hormone also increased. Anger and elation scores on the POMS showed significant concordance in identical twins, as did change in prolactin, implying that these are the components of drug response possibly influenced by genetic factors. None of these responses differentiated well state patients from controls. Thus, mood, behavioral, and neurochemical responses to arecoline, which appears to have nonspecific neurochemical effects at the dose employed, are not markers of vulnerability to affective illness.

Arecoline↗

Reduced plasma and CSF gamma-aminobutyric acid in affective illness: effect of lithium carbonate.

Plasma and CSF gamma-aminobutyric acid (GABA) levels were determined in patients with affective illness and normal volunteers. Plasma GABA was significantly lower in the medication-free euthymic bipolar group (n = 23, p = 0.03) compared to normal volunteers (n = 36). Lithium-treated euthymic bipolar patients (n = 26) tended to have higher plasma GABA levels (p = 0.09) than the medication-free euthymic bipolar group. Plasma GABA in nine patients, measured in the euthymic state on and off lithium, was higher during lithium treatment (p less than 0.02). In CSF, GABA was found to be significantly lower in a group of euthymic medication-free unipolar and bipolar patients (n = 9) compared to normal volunteers (n = 39, p less than 0.02). CSF GABA, on and off lithium in four bipolar patients, was significantly higher during lithium treatment (p less than 0.02). This effect of lithium, increasing CSF and plasma GABA, may be related to its mechanism of therapeutic action.

Adult↗

Platelet vasopressin receptors in bipolar affective illness.

Determinations of the affinity constants (KD) and number of binding sites (Bmax) for platelet vasopressin receptors were done in euthymic bipolar patients and normal volunteers. No significant differences were found between these groups. In addition, lithium treatment did not alter these receptor parameters in the bipolar group.

Adult↗

Vasoactive intestinal peptide and bipolar affective illness. Evidence for an effect of lithium.

In an attempt to evaluate the role of VIP in affective disorder, measurements of lymphocyte VIP receptors, and plasma and CSF VIP levels were made in unmedicated and lithium-treated euthymic bipolars and controls. Lithium decreased plasma (P = 0.01) and CSF (P = 0.05) VIP levels and increased the affinity (decreased the KD) of the VIP lymphocyte receptor (P less than 0.01). This effect may be relevant to the psychotropic action of lithium in manic-depressive illness.

Bipolar Disorder↗